COMPARING THE PREDICTIVE POWER OF COGNITIVE PATIENT REPORTED OUTCOMES FOR EVERYDAY COGNITIVE FUNCTIONING USING ECOLOGICAL MOMENTARY ASSESSMENTS

Ashley M. Henneghan, PhD, RN, FAAN^{1*}; Emily W. Paolillo, PhD²; Kathleen Van Dyk, PhD³; Raeanne C. Moore, PhD⁴

*Presenting Author

¹The University of Texas at Austin School of Nursing ²University of California San Francisco ³University of California Los Angeles

⁴University of California San Diego

Introduction:

- Gaps in knowledge related to the ecological validity of cognitive patient reported outcomes (PROs) to measure cancer-related cognitive impairments (CRCI), and scant evidence directly comparing cognitive PROs limit cross study comparisons and guideline development for research and practice.
- The objective of this study was to determine which cognitive PRO measure best represents self-reported cognitive and everyday functioning in real-world environments using ecological momentary assessments (EMA).


Methods:


- Prospectively enrolled 124 breast cancer survivors
- EMA protocols: 1X/day, every other day X 8 weeks; 1-item ratings for cognitive symptoms, cognitive abilities, social role satisfaction, and well-being (administered via NeuroUX)
- FACT-Cog PCI, PROMIS Cog, Cognitive Failures Questionnaire, and EORTC-CF administered after EMA protocols (T2)
- Person-specific means and standard deviations (within-person variability) calculated for all EMAs
- Pearson's correlations were calculated for cognitive PROs and person-specific EMA variables
- Linear regression model fit parameters (adjusted R2, AIC, BIC) for person-specific means in all EMAs (DVs) were compared for all T2 cognitive PRO measures (IVs)

Results:

- Sample characteristics are displayed in Table 1.
- Correlation patterns were similar among all cognitive PROs and EMAs (Figure 1).
- Model parameters for linear regression models of EMA cognitive symptoms, social role satisfaction, and wellbeing revealed that the FACT-Cog PCI measure best fit the data. See Table 2 for all models parameters.

Table 1. Demographic and Clinical Characteristics of the Sample (N=124) Demographic Characteristic Mean (SD) or Frequency (Percentage) Age in Years 51.4(11.9); range 24-88 Ethnic Minority 15 (12.1%) Racial Minority 33 (26.6%) Partnered 87 (70.2%) Have dependents 63 (50.8%) Employed (part time or full time) Years of Education 17.1 (2.8); range 4-27 Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended 12.2 (1.6); range 0.01 – 5.8 History of stage 0-I breast 54 (43.5%) Cancer History of stage II-III breast 65 (52.4%) Cancer Post-menopausal 79 (63.7%)	O	J
Age in Years Ethnic Minority Racial Minority Partnered Have dependents Employed (part time or full time) Years of Education Clinical Characteristic Years since treatment ended History of stage 0-I breast cancer History of stage II-III breast cancer		
Ethnic Minority Racial Minority Partnered 87 (70.2%) Have dependents 63 (50.8%) Employed (part time or full time) Years of Education 71.1 (2.8); range 4-27 Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended History of stage 0-I breast cancer History of stage II-III breast cancer	Demographic Characteristic	
Racial Minority Partnered 87 (70.2%) Have dependents Employed (part time or full time) Years of Education 17.1 (2.8); range 4-27 Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended History of stage 0-I breast cancer History of stage II-III breast cancer	Age in Years	51.4(11.9); range 24-88
Partnered 87 (70.2%) Have dependents 63 (50.8%) Employed (part time or full 84 (67.7%) time) Years of Education 17.1 (2.8); range 4-27 Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended 2.2 (1.6); range 0.01 – 5.8 History of stage 0-I breast cancer History of stage II-III breast 65 (52.4%) cancer	Ethnic Minority	15 (12.1%)
Have dependents Employed (part time or full time) Years of Education Clinical Characteristic Years since treatment ended History of stage 0-I breast cancer History of stage II-III breast cancer History of stage II-III breast cancer	Racial Minority	33 (26.6%)
Employed (part time or full Years of Education Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended History of stage 0-I breast cancer History of stage II-III breast cancer	Partnered	87 (70.2%)
Years of Education 17.1 (2.8); range 4-27 Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended 2.2 (1.6); range 0.01 – 5.8 History of stage 0-I breast cancer History of stage II-III breast cancer	Have dependents	63 (50.8%)
Clinical Characteristic Mean (SD) or Frequency (Percentage) Years since treatment ended 2.2 (1.6); range 0.01 – 5.8 History of stage 0-I breast cancer History of stage II-III breast cancer		84 (67.7%)
Years since treatment ended 2.2 (1.6); range 0.01 – 5.8 History of stage 0-I breast 54 (43.5%) cancer History of stage II-III breast 65 (52.4%) cancer	Years of Education	17.1 (2.8); range 4-27
History of stage 0-I breast 54 (43.5%) cancer History of stage II-III breast 65 (52.4%) cancer	Clinical Characteristic	
cancer History of stage II-III breast cancer 65 (52.4%)	Years since treatment ended	2.2 (1.6); range 0.01 – 5.8
cancer		54 (43.5%)
Post-menopausal 79 (63.7%)		65 (52.4%)
	Post-menopausal	79 (63.7%)





predictors. Included age, education and time since treatment as covariates in models 5-8, but none were significant predictors. Age, education and time since treatment were covariates in models 9-12, and age approached significance in Model 12 (p = 0.055). Age, education and time since treatment were covariates in models 13-16, but none were significant predicators. *** p < 0.0031 (Bonferroni adjusted p value)

Figure 1. Correlation plot of Cognitive PROs from Time 2 and EMAs (person-specific averages and variability (SD). EMA question for CRCI symptoms— "I have cancer-related cognitive or brain symptoms" (0-7, higher is more symptoms); EMA for Confidence in cognitive abilities— "I am confident in my cognitive abilities (thinking, memory, concentration)" (0-7; higher indicates more confidence); EMA for Social Role Satisfaction—" I feel satisfied with my ability to perform my daily routine and responsibilities"(0-7; higher indicates more satisfaction); EMA question for Wellbeing- "Overall I feel (Excellent (7), Very Good (6), Good (5), Neutral (4), Poor (3), Very Poor (2), Terrible (1)). Significant FDR corrected correlations indicated * p <0.05, ** p < 0.01, *** p < 0.001

Conclusions:

Findings indicate that the FACT-Cog PCI subscale best reflects average cognitive symptoms, social role performance, and overall well-being across time when directly compared to the PROMIS Cog, Cognitive Failures Questionnaire, and EORTC-CF, however the PROMIS Cog was second best for everyday cognitive functioning, and the EORTC-CF second best for social role satisfaction and general well-being.

These findings provide evidence to inform future recommendations/guidelines for regarding which cognitive PROs to use to assess CRCI in research and/or practice.

Acknowledgements:

We acknowledge all the survivors who graciously volunteered to participate in this study. This research was supported by the National Institute for Nursing Research of the National Institutes of Health under award number R21NR020497.



